Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBLG FibroBiologics	$0.62 -13.2%	$0.90	$0.62 ▼ $5.62	$23.65M	-0.8	298,756 shs	3.35 million shs
GLSI Greenwich LifeSciences	$8.99 +0.7%	$9.58	$8.06 ▼ $18.15	$120.18M	1.69	43,488 shs	83,487 shs
IKT Inhibikase Therapeutics	$1.62 -1.8%	$1.96	$1.12 ▼ $4.20	$120.43M	0.94	274,041 shs	7.06 million shs
PRQR ProQR Therapeutics	$2.04 -5.6%	$1.74	$1.07 ▼ $4.62	$214.63M	0.31	655,336 shs	998,760 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBLG FibroBiologics	0.00%	-11.14%	-17.59%	-34.94%	-86.23%
GLSI Greenwich LifeSciences	0.00%	+1.01%	-9.38%	-12.04%	-47.43%
IKT Inhibikase Therapeutics	0.00%	-2.41%	-22.12%	-29.26%	+14.89%
PRQR ProQR Therapeutics	0.00%	+5.70%	+17.24%	+45.71%	+23.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FBLG FibroBiologics	2.6994 of 5 stars	3.6	2.0	2.2	2.5	0.6
GLSI Greenwich LifeSciences	1.6952 of 5 stars	3.5	0.0	1.5	3.3	0.0
IKT Inhibikase Therapeutics	1.5253 of 5 stars	3.3	1.0	0.0	0.0	1.3
PRQR ProQR Therapeutics	1.949 of 5 stars	3.6	3.0	2.5	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FBLG FibroBiologics	3.20	Buy	$13.00	2,003.22% Upside
GLSI Greenwich LifeSciences	3.00	Buy	$39.00	333.82% Upside
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	301.23% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	292.16% Upside

Current Analyst Ratings Breakdown

Latest FBLG, GLSI, IKT, and PRQR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
6/17/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/15/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
5/13/2025	PRQR ProQR Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $9.00
4/29/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$8.00
4/29/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
4/21/2025	GLSI Greenwich LifeSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$38.00 ➝ $39.00
4/9/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/1/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/1/2025	FBLG FibroBiologics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FBLG FibroBiologics	N/A	N/A	N/A	N/A	$0.08 per share	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.19 per share	N/A
IKT Inhibikase Therapeutics	$260K	463.21	N/A	N/A	$1.78 per share	0.91
PRQR ProQR Therapeutics	$20.46M	10.49	N/A	N/A	$0.91 per share	2.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FBLG FibroBiologics	-$11.16M	-$0.21	N/A	N/A	N/A	N/A	-1,022.04%	-117.56%	8/6/2025 (Estimated)
GLSI Greenwich LifeSciences	-$15.79M	-$1.26	N/A	N/A	N/A	N/A	-450.87%	-333.18%	8/12/2025 (Estimated)
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
PRQR ProQR Therapeutics	-$30.04M	-$0.35	N/A	N/A	N/A	-157.04%	-53.49%	-22.07%	8/4/2025 (Estimated)

Latest FBLG, GLSI, IKT, and PRQR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/20/2025	Q1 2025	GLSI Greenwich LifeSciences	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/13/2025	Q1 2025	FBLG FibroBiologics	-$0.10	-$0.14	-$0.04	-$0.14	N/A	N/A
5/8/2025	Q1 2025	PRQR ProQR Therapeutics	-$0.09	-$0.1082	-$0.0182	-$0.11	$4.90 million	$4.89 million
4/15/2025	Q4 2024	GLSI Greenwich LifeSciences	-$0.21	-$0.61	-$0.40	-$0.61	N/A	N/A
3/31/2025	Q4 2024	FBLG FibroBiologics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FBLG FibroBiologics	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FBLG FibroBiologics	N/A	1.14	1.14
GLSI Greenwich LifeSciences	N/A	1.91	1.91
IKT Inhibikase Therapeutics	N/A	0.85	0.85
PRQR ProQR Therapeutics	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FBLG FibroBiologics	N/A
GLSI Greenwich LifeSciences	4.16%
IKT Inhibikase Therapeutics	3.81%
PRQR ProQR Therapeutics	32.65%

Insider Ownership

Company	Insider Ownership
FBLG FibroBiologics	20.00%
GLSI Greenwich LifeSciences	51.67%
IKT Inhibikase Therapeutics	7.30%
PRQR ProQR Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FBLG FibroBiologics	10	38.26 million	30.61 million	N/A
GLSI Greenwich LifeSciences	3	13.37 million	6.46 million	Not Optionable
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable

FBLG, GLSI, IKT, and PRQR Headlines

Recent News About These Companies

ProQR Therapeutics (NASDAQ:PRQR) Earns Market Outperform Rating from JMP Securities

June 29 at 2:01 AM | americanbankingnews.com

ProQR Therapeutics N.V.: ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 27 at 10:21 PM | finanznachrichten.de

ProQR Therapeutics' (PRQR) Market Outperform Rating Reiterated at JMP Securities

June 27 at 8:54 AM | marketbeat.com

ProQR Therapeutics (NASDAQ:PRQR) Receives "Overweight" Rating from Cantor Fitzgerald

June 27 at 8:54 AM | marketbeat.com

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 26 at 4:30 PM | globenewswire.com

Cantor Fitzgerald Comments on PRQR FY2026 Earnings

June 10, 2025 | marketbeat.com

Two Sigma Investments LP Buys 320,614 Shares of ProQR Therapeutics (NASDAQ:PRQR)

June 6, 2025 | marketbeat.com

ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of "Buy" by Analysts

June 5, 2025 | marketbeat.com

ProQR Therapeutics Reports Q1 2025 Financial Results

June 2, 2025 | tipranks.com

ProQR Therapeutics (NASDAQ:PRQR) Short Interest Up 50.9% in May

June 2, 2025 | marketbeat.com

Northern Trust Corp Has $1.11 Million Stock Holdings in ProQR Therapeutics (NASDAQ:PRQR)

May 30, 2025 | marketbeat.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year

May 24, 2025 | investing.com

ProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock News

May 13, 2025 | gurufocus.com

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 12, 2025 | globenewswire.com

ProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Leadership Appointments and Strong Financial Position

May 10, 2025 | nasdaq.com

ProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial Results

May 10, 2025 | finanznachrichten.de

ProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial Results

May 10, 2025 | finanznachrichten.de

New Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR)

May 10, 2025 | finance.yahoo.com

ProQR: Q1 Earnings Snapshot

May 10, 2025 | finance.yahoo.com

ProQR: Q1 Earnings Snapshot

May 10, 2025 | finance.yahoo.com

ProQR Announces First Quarter 2025 Operating and Financial Results

May 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG, GLSI, IKT, and PRQR Company Descriptions

FibroBiologics NASDAQ:FBLG

$0.62 -0.09 (-13.19%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.64 +0.03 (+4.35%)

As of 06/27/2025 07:54 PM Eastern

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Greenwich LifeSciences NASDAQ:GLSI

$8.99 +0.06 (+0.67%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.94 -0.04 (-0.50%)

As of 06/27/2025 07:35 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Inhibikase Therapeutics NYSE:IKT

$1.62 -0.03 (-1.82%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.54 -0.08 (-4.63%)

As of 06/27/2025 07:56 PM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

ProQR Therapeutics NASDAQ:PRQR

$2.04 -0.12 (-5.56%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.08 +0.04 (+1.72%)

As of 06/27/2025 06:44 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time